MiNK Presentation SITC 2021
Marco A. Purbhoo, Burcu Yigit, Darrian Moskowitz, Ayat Alsaraby, Maurice Kirby, Anitha Swarna,
Valeriia Nasonenko, Ilya Mishchenko, Sonia De Munari, Waldo Ortuzar, Koen Van Besien, Don Stevens,
Terese Hammond, Xavier Michelet, Marc van Dijk
November 12, 2021
The CARDIS platform is a 2-stage discovery approach that screens highly diverse scFV libraries followed by selection of extremely potent and safe CARs.
This platform enabled the rapid identification of agenT-F6, MiNK’s allogeneic iNKT-CAR targeting BCMA.
AgenT-F6, iNKT-CAR targeting BCMA, is a highly potent cell therapy product showing cytotoxicity against BCMA expressing tumors cells in vitro and in vivo comparable to the clinical reference.
Invariant Natural Killer T (iNKT) cells are key effectors and regulators of immune responses, making them an ideal immunotherapy.
In cancer, iNKT cells reshape the tumor microenvironment:
In viral lung disease, iNKT cells:
MiNK’s iNKT cell manufacturing is scalable